Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LX9211 for Postherpetic Neuralgia
NCT04662281Phase 2Completed
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Dec 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in postherpetic neuralgia (PHN) comparing Placebo Arm with LX9211 Arm (2 arms). Primary endpoint: Average Daily Pain Score at 6 weeks. Started Dec 2020; status: completed.
02
Drugs
pilavapadin
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT04662281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04662281.